Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations
- 11 June 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 135 (24), 2192-2195
- https://doi.org/10.1182/blood.2019003722
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term VenetoclaxBlood, 2019
- Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax MonotherapyBlood, 2019
- Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemiaHaematologica, 2019
- Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic LeukemiaCancer Discovery, 2019
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2018
- Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemiaNature Communications, 2018
- Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trialThe Lancet Oncology, 2017
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2017
- Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemiaPublished by American Society of Hematology ,2017
- Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphomaBlood, 2014